BioSpace News Archive

FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm.

Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab.

The PPD clinical research business of Thermo Fisher Scientific has been recognized as one of the best in the world for its successful enterprise learning and development programs by the Association for Talent Development (ATD), a global organization that empowers professionals to develop talent in the workplace.

Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Journey Medical and Padagis US LLC (“Padagis”) entered into a settlement agreement pertaining to the patents protecting QBREXZA®.

Data to be Presented in Heavily Pretreated MSS-CRC Speed and Innovation Core to Development Strategy Reduction of 20% in 2022 Operating Costs.

Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business Combination Agreement with DYNS.

Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced positive safety profile results from its joint pre-clinical trial with SciSparc Ltd. (NASDAQ: SPRC).

Nanalysis Announces First Quarter 2022 Conference Call and Virtual Annual General Meeting,

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced the successful completion of its acquisition of Antares Pharma, Inc. (" Antares ").

Acutis, a specialized clinical and biosciences company, announced Dr. Abdel Halim has joined as Chief Scientific Officer and Executive Vice President.